OneSource Specialty Pharma is evaluating the acquisition of sterile injectable businesses from Steriscience Pte. Limited and Brooks Steriscience Limited, including facilities in Poland and India. The company also reported Q1 financial results with 12% revenue growth to ₹3,273 million, 37% EBITDA increase to ₹885 million, and a profit of ₹371 million compared to a loss in the previous year. The company secured 6 new contracts and received 25 RFPs during the quarter.
Onesource Specialty Pharma reported a reduced consolidated net loss of Rs 1.86 million for Q1 FY26, with revenue increasing to Rs 3,272.70 million. The company's Board approved evaluating potential acquisitions of a USFDA-approved facility in Poland and a carbapenem facility in India. Exceptional items of Rs 28.70 million related to Sputnik vaccine litigation impacted results. The company also allotted 59,195 equity shares under its Employee Stock Option Plan.
10Jun 25
ONESOURCE Specialty Pharma Secures VAI Classification from USFDA for Bangalore Facility
ONESOURCE Specialty Pharma has received a 'Voluntary Action Indicated' (VAI) classification from the U.S. Food and Drug Administration for its manufacturing facility in Bangalore, India. This classification indicates that while minor issues were observed, they do not require regulatory action. The VAI status validates the company's compliance with regulatory standards and allows continued operations without significant hurdles. It positions ONESOURCE favorably in the pharmaceutical industry, especially for the U.S. market, while also indicating areas for minor improvements.
10Apr 25
OneSource Specialty Pharma's Unit 2 Secures ANVISA GMP Certification, Expanding Market Reach to Brazil
OneSource Specialty Pharma's Unit 2 in Bengaluru has obtained GMP certification from ANVISA, Brazil's Health Regulatory Agency, following a November 2024 inspection. This approval allows the company to supply Drug-Device Combinations and GLP-1s to the Brazilian market, subject to product approvals. The certification is particularly significant as Brazil is expected to be a major market for generic Semaglutide in 2026. OneSource, formerly Stelis Biopharma, is an Indian specialty pharma CDMO with five globally approved facilities.
07Mar 25
SEBI Guidance Halts OneSource Specialty Pharma's QIP Plans Post-Listing
OneSource Specialty Pharma, a newly listed pharmaceutical company, faces a setback in its capital raising plans due to SEBI guidance. The company is prohibited from conducting a Qualified Institutional Placement (QIP) immediately after listing, owing to its involvement in a merger with an unlisted entity prior to going public. SEBI mandates a one-year waiting period post-listing before OneSource can initiate a QIP. This delay may impact the company's short-term growth strategies and force it to seek alternative funding sources.